Intermedius Genicular Nerve in the Treatment of Patients With Chondromalacia Patella

Summary

Radiofrequency application is a treatment method that temporarily prevents the transmission of pain in the nerve where the application is made through the heat emitted by radio waves.Partial inhibition of the functions of the nerves carrying the joint pain sensation with this method is the basis of the treatment.The intermedius genicular nerve carries the sensation of subpatellar pain due to chondromalacia.In this study,investigators aim is to investigate the effect of radiofrequency neurotomy applied to the intermedius genicular nerve, which receives the sensation of the patella, on pain and knee function in patients with a diagnosis of chondromalacia patella who have anterior knee pain that does not resolve despite conservative treatment, under the guidance of ultrasonography.

Conditions

• Chondromalacia Patellae

Interventions

PROCEDURE

radiofrequency

the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.

PROCEDURE

control

The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.

DRUG

2% lidocaine

2% lidocaine

Sponsors & Collaborators

• Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

  lead OTHER

Principal Investigators

• Serdar KESİKBURUN, MD · SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

• Burak BAYIR, MD · SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

• Özlem KÖROĞLU, MD · SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

• Esra ÇELİK KARBANCIOĞLU, MD · SBU,Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-05-15

Primary Completion

2022-07-15

Completion

2022-07-15

Countries

• Turkey (Türkiye)

Study Locations